Dr.Reddy's settles patent litigation with Glaxo

Dr Reddy's Laboratories has settled patent litigation with Glaxo SmithKline (GSK) relating to sumatriptan succinate tablets, the generic version of GSK's Imitrex.

According to Dr Reddy's Labs' release to the BSE, the terms of the settlement, subjected to government review, provide that the company may exclusively distribute an authorized generic version of Sumatriptan tablets (in the 25 mg, 50 mg and 100 mg strengths) in the US during the fourth quarter of 2008.

The release added that, Imitrex tablets, indicated for the acute treatment of migraine attacks in adults, had US sales of $890 million for the 12 month period ending June, 2006.